NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

Inclusion Criteria: 1. Women ≥ 18 years old 2. Histologically or cytologically confirmed diagnosis of breast cancer 3. Naïve patients 4. Be scheduled to receive adjuvant chemotherapy with anthracycline (doxorubicin or epirubicin) + cyclophosphamide (AC-based regimen) 5. ECOG (Eastern Cooperative Oncology Group) performance status 0-2 6. Body Mass index (BMI) ≥ 18.5 7. Written informed consent 8. If women of childbearing potential age: reliable contraceptive measures must be used during the study treatment period and up to 30 days after last NEPA administration 9. Acceptable hepatic function (\<= 2 times the upper limit of normal for liver transaminases) and renal function (creatinine \< 1.5 times the upper limit of normal); 10. Ability and willingness of the patient to complete the diary. Exclusion Criteria: 1. Advanced/metastatic breast cancer 2. Patients already submitted to non-AC-based chemotherapy 3. Treatment with investigational medications in 30 days before NEPA 4. Myocardial infarction within the last 6 months 5. Documented or known hypersensitivity to 5HT3RA (5-Hydroxytryptamine Receptor 3 Antagonists) or NK1RA (Neurokinin-1 Receptor Antagonists) and excipients 6. Uncontrolled diabetes mellitus 7. Nausea and vomiting at baseline 8. Chronic use of other antiemetic agent(s) 9. Patient's inability to take oral medication 10. Gastrointestinal obstruction or active peptic ulcer 11. Pregnancy or breastfeeding 12. Prior malignancies at other sites except surgically treated non-melanoma skin cancer, superficial cervical cancer, or other cancer from which the patient had been disease-free for ≥ 5 years 13. Psychiatric or CNS (Central Nervous System) disorders interfering with ability to comply with study protocol